This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Lung Cancer
  • /
  • Final overall survival and safety update for durva...
Journal

Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study

Read time: 1 mins
Published:31st Aug 2020
Author: Garassino MC, Cho BC, Kim JH, Mazières J, Vansteenkiste J, Lena H et al.
Source: Lung Cancer
Availability: Free full text
Ref.:Lung Cancer. 2020 Sep;147:137-142.
DOI:10.1016/j.lungcan.2020.06.032
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest